Arrowgrass Capital Partners (US)’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-130,700
Closed -$41.6M 176
2017
Q4
$41.6M Buy
130,700
+129,093
+8,033% +$41.4M 0.4% 50
2017
Q3
$50.3M Sell
1,607
-305
-16% -$90.3K 0.37% 64
2017
Q2
$51.9M Buy
1,912
+1,164
+156% +$308K 0.39% 64
2017
Q1
$20.5M Sell
748
-436
-37% -$123K 0.21% 136
2016
Q4
$33.6M Sell
1,184
-144
-11% -$42.7K 0.38% 61
2016
Q3
$41.6M Buy
1,328
+209
+19% +$61.9K 0.56% 43
2016
Q2
$27.1M Buy
1,119
+261
+30% +$68.8K 0.29% 56
2016
Q1
$22.3M Buy
858
+658
+329% +$174K 0.27% 65
2015
Q4
$6.13M Buy
+200
New +$57.5K 0.07% 141
2015
Q3
Sell
-110
Closed -$4.44M 462
2015
Q2
$4.44M Buy
+110
New +$44.1K 0.07% 224
2015
Q1
Sell
-34,800
Closed -$11.8M 418
2014
Q4
$11.8M Buy
+34,800
New +$11.3M 0.21% 70

Other funds holding BIIB

Arrowgrass Capital Partners (US)'s BIIB Position: Q3 2017 in Review

Arrowgrass Capital Partners (US) sold out of Biogen (BIIB) in Q3 2017, closing a stake of 56,916 shares — an estimated $16.9M sold.

Arrowgrass Capital Partners (US) first reported a position in BIIB in Q2 2015 and held it in 7 quarters. The position peaked at $18.4M in Q1 2017. 1,015 funds tracked by Wall St. Rank hold BIIB as of Q3 2017.

  • Arrowgrass Capital Partners (US) reported no remaining Biogen position as of Q3 2017 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 56,916 Biogen shares in Q3 2017, an estimated $16.9M.
  • Arrowgrass Capital Partners (US) first reported a position in Biogen in Q2 2015 and held it in 7 quarters.
  • Arrowgrass Capital Partners (US)'s Biogen position peaked at $18.4M in Q1 2017.
  • 1,015 funds tracked by Wall St. Rank held Biogen as of Q3 2017.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2017, filed 14 Nov 2017.